

The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein $a^1-a^2=a^3-a^4$ represents a divalent radical selected from N-CH=CH-CH, N-CH-N-CH or CH-CH=N-CH; Z represents NH; Y represents -C₃₋₉alkyl-, -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₆alkyl-NH-CO- or -CO-NH-C₁₋₆alkyl-; X¹ represents -O- or -NR¹¹-; X² represents -C₁₋₂alkyl-, -O-C₁₋₂alkyl-, -O- or -O-CH₂; R¹ represents hydrogen or halo; R² represents hydrogen, cyano, halo, hydroxycarbonyl-C₁₋₄alkyloxycarbonyl-, Het¹⁶-carbonyl- or Ar⁵; R³ represents hydrogen; R⁴ represents hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents C₁₋₄alkyloxy substituted with one or where possible two or more substituents selected from C₁₋₄alkyloxy- or Het²-; R¹¹ represents hydrogen; R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-; R¹³ represents Het¹⁴-C₁₋₄alkyl, in particular morpholinyl-C₁₋₄alkyl; Het² represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl; Het¹⁴ represents morpholinyl; Het¹⁶ represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar⁴ represents phenyl; Ar⁵ represents phenyl optionally substituted with cyano.

